Allergy Therapeutics reports positive results from Acarovac trial

UK-based allergy vaccine specialist Allergy Therapeutics (LSE: AGY) has announced positive results from its prospective observational Acarovac Plus clinical study for the treatment of house dust mite allergy.

Acarovac Plus is being developed as part of Allergy Therapeutics’ new generation of products for the perennial allergy market. It is designed to administer maintenance doses every six to eight weeks, reducing the number of annual injections required and providing a natural, biodegradable alternative depot vaccine.

The drug's tolerability was demonstrated with no reported adverse events. Its effectiveness was measured in patients using a nasal provocation test, evaluating the sensitivity of each patient to mite allergens. A reduction in symptom scores of more than 50% were observed during follow-up visits after one year, as well as an assessment of immunological markers showing significant improvements in antibody IgG4 and anti-inflammatory IL-10 molecules, indicating tolerance induction in patients after one year of treatment.